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ABSTRACT
Background. Although the Barcelona Clinic Liver Cancer
(BCLC) staging system has been largely adopted in clinical
practice, recent studies have questioned the prognostic
stratification of this classification schema, as well as the
proposed treatment allocation of patients with a single
large tumor.
Methods. Patients who underwent curative-intent hepate-
ctomy for histologically proven hepatocellular carcinoma
(HCC) between 1998 and 2017 were identified using an
international multi-institutional database. Overall survival
(OS) among patients with BCLC stage 0, A, and B was
examined. Patients with a single large tumor were classi-
fied as BCLC stage A1 and were independently assessed.
Results. Among 814 patients, 68 (8.4%) were BCLC-0,
310 (38.1%) were BCLC-A, 279 (34.3%) were BCLC-A1,
and 157 (19.3%) were BCLC-B. Five-year OS among
patients with BCLC stage 0, A, A1, and B HCC was
86.2%, 69.0%, 56.9%, and 49.9%, respectively
(p\ 0.001). Among patients with very early- and early-
stage HCC (BCLC 0, A, and A1), patients with BCLC
stage A1 had the worst OS (p = 0.0016). No difference in
survival was noted among patients undergoing surgery for
BCLC stage A1 and B HCC (5-year OS: 56.9% vs. 49.9%;
p = 0.259) even after adjusting for competing factors
(hazard ratio 0.83, 95% confidence interval 0.54–1.28;
p = 0.40).
Conclusion. Prognosis following liver resection among
patients with BCLC-A1 HCC was similar to patients pre-
senting with BCLC-B tumors. Surgery provided
acceptable long-term outcomes among select patients with
BCLC-B HCC. Designation into BCLC stage B should not
be considered an a priori contraindication to surgery.
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Hepatocellular carcinoma (HCC) accounts for over 70%
of primary liver malignancies and has had an increased
incidence and cancer-related mortality over the past 2
decades.1 Surgery, in the form of resection, ablation or
liver transplantation, remains the mainstay of treatment for
patients with resectable disease.2,3 Several staging systems
have been proposed to define the prognosis of patients with
HCC, as well as inform treatment recommendations.4,5 The
Barcelona Clinic Liver Cancer (BCLC) system is unique in
that it seeks to determine patient prognosis, as well as
recommends specific treatment algorithms based on HCC
tumor stage.6 To this point, the BCLC staging system
recommends that only patients with very early- and early-
stage (BCLC stage 0 and A, respectively) HCC should
undergo surgical resection. In contrast, patients with
intermediate (BCLC stage B) and advanced (BCLC stage
C) stage HCC are recommended to receive transarterial
chemoembolization (TACE) or sorafenib, respectively.2,6
In 2011, the original BCLC system was updated to
designate a single large HCC (C 5 cm) as BCLC stage A
rather than stage B.7 The revised BCLC classification
schema has been endorsed by the European Association for
the Study of the Liver (EASL),2 as well as the American
Association for the Study of Liver Diseases (AASLD).3
Nevertheless, increasing tumor size has been associated
with a higher incidence of microvascular invasion, a known
risk factor for recurrence.8,9 As such, several investigators
have questioned the classification of single large tumor as
BCLC stage A.10,11 In turn, the prognostic discrimination
of the revised BCLC classification has come into question.
In addition, some surgeons have advocated for liver
resection in select patients with intermediate (BCLC stage
B) or even advanced (BCLC stage C) stage HCC, which is
beyond the current BCLC treatment guidelines.12 For
example, in a report of 85 patients with multinodular
BCLC stage B HCC, Wada et al. reported a 5-year overall
survival (OS) of 63.4% and concluded that designation as
BCLC stage B should not be an absolute contraindication
to surgery.12 Given the debate as to whether the revised
BCLC system performs well in terms of prognostic strati-
fication and treatment allocation for patients with various
stages of HCC, we sought to characterize the outcomes of
patients undergoing liver resection for BCLC stage 0, A,
and B HCC. Specifically, the objective of the current study
was to determine whether the updated BCLC staging sys-
tem performed well in stratifying patients with HCC
relative to long-term prognosis, with a particular focus on
the differences among patients with a single large HCC
(i.e. stage A) versus stage B HCC.
MATERIALS AND METHODS
Study Population and Data Collection
Patients who underwent resection of HCC between 1998
and 2017 were identified from an international multi-in-
stitutional database. Patients were treated at one of the 11
participating institutions: The Ohio State University Wex-
ner Medical Center, Columbus, OH, USA; Yokohama City
University School of Medicine, Yokohama, Japan;
University of Verona, Verona, Italy; Ospedale San Raf-
faele, Milano, Italy; Curry Cabral Hospital, Lisbon,
Portugal; APHP, Beaujon Hospital, Clichy, France; West-
mead Hospital, Sydney, NSW, Australia; Stanford
University, Stanford, CA, USA; Fundeni Clinical Institute,
Bucharest, Romania; University of Ottawa, Ottawa, ON,
Canada; and The University of Sydney, School of Medi-
cine, Sydney, NSW, Australia. Patients were followed and
outcomes were recorded in a prospectively maintained
multi-institutional database. Patients with very early
(BCLC stage 0), early (BCLC stage A) or intermediate
(BCLC stage B) stage HCC, according to the latest BCLC
staging system,2 were included in the analytic cohort.
Patients with advanced stage (BCLC stage C) HCC and
individuals without follow-up data were excluded from the
analysis. The study was approved by the Institutional
Review Boards of all participating institutions.
Variables and Outcomes of Interest
The primary outcome was OS, which was defined as the
time interval between the date of hepatectomy and the date
of death or last follow-up. The primary independent vari-
able was the BCLC stage as defined by the latest EASL
guidelines.2 In brief, BCLC 0 was defined as a single
tumor\ 2 cm; BCLC A was defined as a single tumor
2–5 cm or two to three nodules, all\ 3 cm; and BCLC B
referred to two to three nodules C 3 cm or C 4 nodules.
For the purpose of this study, patients with a single large
HCC (C 5 cm) were subclassified as BCLC stage A1
(Fig. 1).
Demographic and clinical data included age, sex,
American Society of Anesthesiologists (ASA) score,
Charlson Comorbidity Index score (CCS), history of cir-
rhosis, hepatitis B virus (HBV)/hepatitis C virus (HCV)
infection, ascites within 30 days prior to surgery, body
mass index (BMI), laboratory values (i.e. a-fetoprotein
[AFP], platelet count [PLT], albumin, total bilirubin, ala-
nine aminotransferase [ALT], aspartate aminotransferase
[AST], prothrombin time [PT]), Child–Pugh liver function,
BCLC classification, type of surgical resection (i.e. major
or minor), minimally invasive surgery, tumor grade, tumor
size, pathologic lymphovascular invasion and liver capsule
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involvement, as well as margin status (i.e. R0, R1, or R2).
Major hepatectomy was defined as resection of three or
more Couinaud segments.
Statistical Analysis
Descriptive statistics were presented as median (in-
terquartile range [IQR]) and frequency (%) for continuous
and categorical variables, respectively. Bivariate survival
analyses were performed using the log-rank test and were
presented using Kaplan–Meier curves. Multivariable sur-
vival analyses were performed using Cox proportional
hazards regression analysis. The level of statistical signif-
icance was set at a = 0.05. All analyses were performed
using STATA version 12.0 (StataCorp LLC, College Sta-
tion, TX, USA).
RESULTS
Patient and Tumor Characteristics
The analytic cohort was comprised of 814 patients with
HCC who underwent surgical resection and met the
inclusion criteria. Overall, patients were categorized into
BCLC 0 (n = 68, 8.4%), BCLC A (n = 310, 38.1%),
BCLC A1 (n = 279, 34.3%), and BCLC B (n = 157,
19.3%) stage (Fig. 1). Among the entire cohort, median
patient age was 68 years (IQR 60–74), most patients were
male (n = 628, 77.3%), and had an ASA score of [ 2
(n = 457, 57.7%) and CCS of[ 3 (n = 448, 55%)
(Table 1). A history of cirrhosis, as well as HBV and HCV
infection was present in 37.6% (n = 306), 16.5%
(n = 134), and 31.4% (n = 253) of patients, respectively.
Only a minority of individuals had ascites prior to surgery
(n = 28, 3.4%). Median tumor size was 5 cm (IQR 3–9)
and most tumors were well/moderately differentiated
(n = 646, 80.8%). Approximately one-quarter of patients
underwent minimally invasive surgery (n = 205, 25.2%);
approximately one-third had a major resection (n = 290,
36.1%). The vast majority of patients had R0 HCC
resection (n = 658, 81.6%). On histological examination,
42.7% (n = 336) of patients had lymphovascular invasion,
whereas liver capsule involvement was present in 36.6%
(n = 230) of patients. Median follow-up was 29.5 months
(IQR 14.5–51.1).
Survival Analysis: Barcelona Clinic Liver Cancer
(BCLC) Stage 0, A, A1, and B Hepatocellular
Carcinoma (HCC)
Several variables were associated with prognosis after
HCC resection (Table 2). Of note, survival was associated
with BCLC staging classification; 5-year OS among
patients with BCLC stage 0, A, A1, and B HCC was 86.2%
(95% confidence interval [CI] 66.2–94.8), 69.0% (95% CI
60.8–75.8), 56.9% (95% CI 47.5–65.3), and 49.9% (95%
CI 37.8–60.9), respectively (p\ 0.001). Among patients
with very early- and early-stage HCC (BCLC 0, A, and
A1), patients with BCLC stage A1 (single tumors C 5 cm)
had the worst OS (p = 0.0016) (Fig. 2a). Perhaps of more
interest, there was no difference in survival between
patients undergoing surgery for BCLC stage A1 and stage
B HCC (3-year OS: 71.7% vs. 65.5%; 5-year OS: 56.9%
vs. 49.9%; p = 0.259) (Fig. 2b).
Survival Analysis: Other factors
Apart from BCLC stage, several other factors were
associated with survival (Table 2). Of note, patients with
AFP B 400 ng/mL had a 5-year OS of 65.7% (95% CI
59.6–71.1) versus 53.5% (95% CI 43.1–62.8) among
patients with AFP[ 400 ng/mL (p\ 0.001). In addition,
5-year OS decreased from 67.1% (95% CI 61.2–72.3)
among patients with well/moderately differentiated tumors
to 44.0% (95% CI 32.6–54.7) for poorly/undifferentiated
tumors (p\ 0.001). Patients undergoing major resection
had a 5-year OS of 57.2% (95% CI 48.6–64.9) versus
66.1% (95% CI 59.3–72.0) among individuals who
underwent a minor resection (p = 0.008). Perhaps not
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FIG. 1 Schematic presentation of BCLC stage 0, A, A1, and B hepatocellular carcinoma. BCLC Barcelona Clinic Liver Cancer
Liver Resection for BCLC Stage 0, A, and B HCC 3695
invasion (p\ 0.001), liver capsule involvement
(p\ 0.001), or R1/R2 (p = 0.004) had worse 5-year OS
than their respective counterparts.
Multivariable Survival Analysis
On multivariable analysis, compared with patients with
BCLC stage B HCC, patients with BCLC stage 0 (hazard
TABLE 1 Demographics and patient characteristics in the entire
cohort (N = 814)
Variable
Age, years [median (IQR)] 68 (60–74)
B 65 317 (38.9)





B 2 335 (42.3)
[ 2 457 (57.7)
Charlson comorbidity index score
B 3 366 (45.0)














\ 17.5 15 (1.8)
17.5–30 566 (69.5)
C 30 233 (28.6)
Platelet count, 9 103/lL
B 150 253 (31.1)
[ 150 561 (68.9)
Albumin, g/dL
B 3.5 174 (21.4)
[ 3.5 640 (78.6)
Total bilirubin, mg/dL
B 1.2 732 (89.9)
[ 1.2 82 (10.1)
AST, U/L
B 40 334 (41.6)
[ 40 469 (58.4)
ALT, U/L
B 56 528 (65.4)
[ 56 280 (34.7)
PT/INR
B 1.1 629 (77.3)




B 400 581 (71.4)















Tumor size, cm [median (IQR)] 5 (3–9)
Grade
Well to moderate 646 (80.8)











Data are expressed as n (%) unless otherwise specified
IQR interquartile range, ASA-PS American Society of Anesthesiolo-
gists performance score, HBV hepatitis B virus, HCV hepatitis C
virus, BMI body mass index, AST aspartate aminotransferase, ALT
alanine aminotransferase, AFP a-fetoprotein, PT prothrombin time,
BCLC Barcelona Clinic Liver Cancer, INR international normalized
ratio
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TABLE 2 Factors associated with 3- and 5-year survival in the entire cohort (N = 814)
Variable 3-year OS (%) 95% CI 5-year OS (%) 95% CI p value
Age, years 0.480
B 65 76.8 70.7–81.8 63.7 55.5–70.8
[ 65 74.8 69.6–79.2 61.8 54.9–67.9
Sex 0.487
Male 74.9 70.4–78.7 61.3 55.2–66.8
Female 78.0 69.6–84.4 66.2 55.2–75.0
ASA-PS 0.430
B 2 77.7 71.4–82.7 62.8 53.5–70.7
[ 2 75.2 70.0–79.5 64.0 57.3–70.0
Charlson comorbidity index score 0.102
B 3 75.9 70.5–80.5 68.2 61.8–73.8
[ 3 75.2 69.5–80.1 53.5 44.4–61.7
Cirrhosis 0.387
No 77.6 71.3–82.7 57.9 48.3–66.3
Yes 74.4 69.4–78.7 64.8 58.6–70.4
HBV infection 0.302
No 75.2 70.9–78.9 60.5 54.6–65.9
Yes 77.8 68.1–84.9 70.9 59.6–79.6
HCV infection 0.653
No 73.5 68.7–77.8 62.6 56.3–68.2
Yes 79.7 73.0–84.9 62.3 52.2–70.8
AFP, ng/mL \ 0.001
B 400 78.7 74.3–82.4 65.7 59.6–71.1
[ 400 67.3 59.1–74.2 53.5 43.1–62.8
Child–Pugh classification 0.987
A 75.6 71.7–79.1 62.9 57.6–67.7
B 75.4 49.5–89.3 52.8 20.9–77.0
BCLC staging classification \ 0.001
0 91.9 79.6–97.0 86.2 66.2–94.8
A 80.5 74.4–85.3 69.0 60.8–75.8
A1 71.7 64.9–77.4 56.9 47.5–65.3
B 65.5 54.9–74.2 49.9 37.8–60.9
Type of resection 0.008
Minor 80.0 75.3–83.8 66.1 59.3–72.0
Major 68.7 61.7–74.8 57.2 48.6–64.9
Grade \ 0.001
Well to moderate 78.7 74.5–82.3 67.1 61.2–72.3
Poor to undifferentiated 61.8 52.1–70.1 44.0 32.6–54.7
Lymphovascular invasion \ 0.001
No 84.1 79.5–87.7 70.3 63.6–76.0
Yes 62.7 55.8–68.8 52.8 44.2–60.7
Liver capsule involvement \ 0.001
No 76.8 71.4–81.3 64.7 58.0–70.7
Yes 62.9 55.0–69.8 52.5 43.5–60.7
Margin status 0.004
R0 77.0 72.8–80.6 63.7 58.1–68.8
R1 71.2 59.4–80.1 59.5 42.6–73.0
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ratio [HR] 0.22, 95% CI 0.08–0.63; p = 0.005) and BCLC
stage A (HR 0.62, 95% CI 0.39–0.98; p = 0.043) HCC had
78% and 38% decreased hazards of death, respectively
(Table 3). Nevertheless, after controlling for all measur-
able confounding factors, no difference in survival was
noted among patients with BCLC stage A1 and B HCC
(HR 0.83, 95% CI 0.54–1.28; p = 0.40). In contrast,
AFP[ 400 ng/mL (HR 1.41, 95% CI 1.00–1.97;
p = 0.047), presence of microscopic lymphovascular
invasion (HR 1.83, 95% CI 1.32–2.55; p\ 0.001), and R2
margin status (HR 2.36, 95% CI 1.08–5.17; p = 0.031)
were all associated with a higher hazard of death.
Subgroup Analysis: Factors Associated with Overall
Survival Among BCLC Stage A1 and B HCC
Among patients with BCLC stage A1 and B HCC,
patients with AFP B 400 ng/mL had a 5-year OS of 60.0%
(95% CI 50.6–68.1) versus 44.5% (95% CI 32.5–55.8) for
individuals with AFP[ 400 ng/mL (p\ 0.001) [Elec-
tronic Supplementary Table S1]. In addition, poorly/
undifferentiated tumor grade, presence of lymphovascular
invasion, and R1/R2 margin status were all associated with
worse 5-year OS (all p\ 0.001).
DISCUSSION
Prognostic assessment is critical to construct the
appropriate therapeutic strategy for patients diagnosed with
HCC.4 The BCLC classification system not only assesses
patient prognosis but also assigns treatment allocation
based on prognostic subclasses.2,6 Although this system has
been largely adopted in the West, there has recently been a
growing skepticism as to whether the current BCLC
TABLE 2 continued
Variable 3-year OS (%) 95% CI 5-year OS (%) 95% CI p value
R2 49.9 18.9–74.8 24.9 1.6–62.7
OS overall survival, CI confidence interval, IQR interquartile range, ASA-PS American Society of Anesthesiologists performance score, HBV
hepatitis B virus, HCV hepatitis C virus, AFP a-fetoprotein, BCLC Barcelona Clinic Liver Cancer
TABLE 3 Multivariable analysis of survival
Variable HR 95% CI p value
AFP, ng/mL
B 400 Ref
[ 400 1.41 1.00–1.97 0.047
BCLC staging classification
0 0.22 0.08–0.63 0.005
A 0.62 0.39–0.98 0.043




Yes 1.83 1.32–2.55 \ 0.001
Margin status
R0 Ref
R1 0.81 0.51–1.29 0.373
R2 2.36 1.08–5.17 0.031
AFP a-fetoprotein, BCLC Barcelona Clinic Liver Cancer, HR hazard
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FIG. 2 Kaplan–Meier curves demonstrating differences in survival among patients with a BCLC stage 0, A, and A1 HCC, and b BCLC stage
A1 versus stage B HCC. BCLC Barcelona Clinic Liver Cancer, HCC hepatocellular carcinoma
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classification performs well in terms of prognostic strati-
fication, especially for patients with a single large tumor,
which was previously considered BCLC stage B.11,13 In
addition, a growing number of studies have advocated for
liver resection outside the BCLC criteria, suggesting a
shortcoming of the current stage-specific treatment pro-
posed by the BCLC system.14–16 The current study was
important because we specifically assessed the outcomes of
patients undergoing surgery for HCC within (BCLC stage 0
and A) and outside (BCLC stage B) the BCLC criteria
using an international multi-institutional database. Of note,
among patients with very early- and early-stage HCC,
patients with a single large tumor (C 5 cm; BCLC stage
A1) had the worst OS. Perhaps of more interest, patients
undergoing surgery for BCLC stage A1 HCC (within the
BCLC criteria) had long-term outcomes comparable with
patients undergoing surgery for BCLC stage B HCC
(outside the BCLC criteria), even after controlling for all
possible competing risk factors. These results indicate that
while a single large tumor should be considered BCLC
stage A in terms of treatment allocation (i.e. surgery),
BCLC stage B is likely a better designation for these
patients in terms of prognosis. In addition, these data
support the notion that designation into BCLC stage B
should not be considered an a priori contraindication to
surgery, especially among patients with resectable tumors.
Previous studies have demonstrated that patients with
HCC exceeding 5 cm have a distinct, worse prognosis
compared with patients who have a smaller solitary
tumor.11,15 Indeed, increasing tumor size has been associ-
ated with higher rates of microvascular invasion and more
advanced histologic grade, both of which are known to
increase recurrence rates.8,9 In fact, one previous study
noted that the incidence of microvascular invasion nearly
doubled among patients with tumors larger than 5 cm
(61%) compared with smaller tumors (32%), and continued
to increase among tumors larger than 10 cm.9 In turn,
patients with a solitary large tumor had higher recurrence
rates and thus worse survival.9 Given these data, several
investigators have suggested that these patients should be
classified as BCLC stage B, rather than BCLC stage A.13,17
In the current study, among the 279 patients with a single
large tumor, we noted that these patients had markedly
worse prognosis compared with other patients who had
early (BCLC stage A) or very early (BCLC stage 0) stage
tumors (5-year OS: 56.9% vs. 69.0% vs. 86.2%, respec-
tively; p = 0.0016). Perhaps of more interest, the prognosis
of these patients was similar to patients who had BCLC
stage B tumors, even after controlling for all measured
competing risk factors (HR 0.83, 95% CI 0.54–1.28;
p = 0.40). As such, data from the current study strongly
suggest that patients with a single large HCC would be
more appropriately classified as BCLC stage B in terms of
prognosis.
While surgery for a single large HCC has been associ-
ated with acceptable long-term outcomes,14–16 the current
BCLC classification recommends that patients with BCLC
stage B should undergo TACE2. However, an increasing
body of evidence has revealed that liver resection may be
justified in select patients with intermediate (BCLC B) or
even advanced (BCLC C) stage HCC.18–20 In a recent
propensity score matched study, Kim et al. compared the
outcomes of patients with BCLC stage B HCC following
surgery (n = 80) versus no surgical treatment (n = 80).18
The authors reported a 5-year OS of 63% among patients
who underwent resection versus only 22% for patients in
the non-surgical cohort.18 These data suggested that sur-
gery can offer a survival benefit for potentially
resectable BCLC stage B HCC. In a separate study, Wada
et al. reported on patients with multinodular BCLC stage B
HCC undergoing liver resection and demonstrated an
acceptable 5-year OS of 63.4%.12 In addition, increasing
evidence suggests that patients undergoing an anatomic
resection may have improved outcomes compared with
individuals who undergo a non-anatomic resection.2,21
Indeed, with an anatomic resection of the liver, Glisson
pedicles are ligated and cut off in advance.22 In turn,
microvascular invasive lesions, thought to be strongly
correlated with disease relapse and more frequently noted
in patients with single large tumors ([ 5 cm) or multifocal
disease (i.e. BCLC A1 or BCLC B), may be more appro-
priately removed with anatomic resection of the liver
provided that the patient has adequate liver remnant.21,22
The current study is one of the largest cohorts of patients
undergoing liver resection outside the BCLC criteria
(n = 157 patients with BCLC stage B HCC) reported in the
literature.20,23,24 By exclusively analyzing BCLC stage B
patients who underwent resection, we were able to deter-
mine that the 5-year OS of 49.9% (95% CI 37.8–60.9) was
similar to patients having BCLC stage A1 tumors. Thus,
the data support surgery as being beneficial in select
patients with BCLC stage B HCC. In addition, designation
to BCLC stage B per se should not be considered a con-
traindication to surgery. Rather, preoperative AFP levels[
400 ng/ml were strongly associated with worse long-term
outcomes and should be taken into consideration when
planning surgery for patients outside the Barcelona criteria.
The results of the current study should be interpreted in
the context of certain limitations. The retrospective nature
of the study may have introduced some selection biases,
(i.e. patients with BCLC stage B HCC had potentially
resectable tumors and more favorable tumor biology), and
as such the results should only be applied to select patients
with HCC. In addition, the lack of a comparison group (i.e.
Liver Resection for BCLC Stage 0, A, and B HCC 3699
TACE for BCLC stage B patients) did not allow us to draw
definitive conclusions over the superiority of different
treatment approaches in the management of patients.
CONCLUSIONS
The prognosis of patients with a single large HCC was
worse compared with other BCLC stage A patients, but
was similar to patients presenting with BCLC stage B
tumors following liver resection. Surgery provided
acceptable long-term outcomes among select patients with
BCLC stage B HCC. Designation into BCLC stage B
should not be considered an a priori contraindication to
surgery among patients with resectable tumors. While
patients with a single large HCC should be treated as
BCLC A patients, their prognosis was more akin to BCLC
B patients. This point further highlights that the confluence
of staging and treatment allocation characterized in the
BCLC staging system may represent an oversimplification
of how to care for patients with HCC.
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